Cargando…
Zonisamide improves axial symptoms in dementia with Lewy bodies with parkinsonism: Post hoc analysis of clinical trials()
Patients with dementia with Lewy bodies (DLB) experience worsening axial symptoms with disease progression, which can negatively affect quality of life. Previous phase 2 and 3 clinical trials conducted in Japan showed that zonisamide improved parkinsonism in patients with DLB. In the present study,...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8703232/ https://www.ncbi.nlm.nih.gov/pubmed/34988303 http://dx.doi.org/10.1016/j.ensci.2021.100384 |
_version_ | 1784621414114918400 |
---|---|
author | Tsuboi, Yoshio Kochi, Kenji Maruyama, Hidenori Matsumoto, Yuji |
author_facet | Tsuboi, Yoshio Kochi, Kenji Maruyama, Hidenori Matsumoto, Yuji |
author_sort | Tsuboi, Yoshio |
collection | PubMed |
description | Patients with dementia with Lewy bodies (DLB) experience worsening axial symptoms with disease progression, which can negatively affect quality of life. Previous phase 2 and 3 clinical trials conducted in Japan showed that zonisamide improved parkinsonism in patients with DLB. In the present study, we performed a post hoc analysis of pooled data from the previous phase 2 and 3 trials to examine the effect of zonisamide on axial symptoms in this patient group. In our pooled analysis, the primary outcome was the change from baseline to 12 weeks in axial symptom score, measured as the sum of Unified Parkinson's Disease Rating Scale Part III items relevant to gait/balance/midline function. A total of 498 patients were included in this analysis. Zonisamide 25 mg and 50 mg significantly reduced the axial symptom score at week 12 compared with placebo (p < 0.01 and p < 0.001, respectively, by mixed model of repeated measures). Our findings indicate that zonisamide may improve axial symptoms in DLB with parkinsonism and, thus, may potentially reduce the risk of falls and improve quality of life in this vulnerable patient population. |
format | Online Article Text |
id | pubmed-8703232 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-87032322022-01-04 Zonisamide improves axial symptoms in dementia with Lewy bodies with parkinsonism: Post hoc analysis of clinical trials() Tsuboi, Yoshio Kochi, Kenji Maruyama, Hidenori Matsumoto, Yuji eNeurologicalSci Original Article Patients with dementia with Lewy bodies (DLB) experience worsening axial symptoms with disease progression, which can negatively affect quality of life. Previous phase 2 and 3 clinical trials conducted in Japan showed that zonisamide improved parkinsonism in patients with DLB. In the present study, we performed a post hoc analysis of pooled data from the previous phase 2 and 3 trials to examine the effect of zonisamide on axial symptoms in this patient group. In our pooled analysis, the primary outcome was the change from baseline to 12 weeks in axial symptom score, measured as the sum of Unified Parkinson's Disease Rating Scale Part III items relevant to gait/balance/midline function. A total of 498 patients were included in this analysis. Zonisamide 25 mg and 50 mg significantly reduced the axial symptom score at week 12 compared with placebo (p < 0.01 and p < 0.001, respectively, by mixed model of repeated measures). Our findings indicate that zonisamide may improve axial symptoms in DLB with parkinsonism and, thus, may potentially reduce the risk of falls and improve quality of life in this vulnerable patient population. Elsevier 2021-12-07 /pmc/articles/PMC8703232/ /pubmed/34988303 http://dx.doi.org/10.1016/j.ensci.2021.100384 Text en © 2021 The Authors. Published by Elsevier B.V. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Original Article Tsuboi, Yoshio Kochi, Kenji Maruyama, Hidenori Matsumoto, Yuji Zonisamide improves axial symptoms in dementia with Lewy bodies with parkinsonism: Post hoc analysis of clinical trials() |
title | Zonisamide improves axial symptoms in dementia with Lewy bodies with parkinsonism: Post hoc analysis of clinical trials() |
title_full | Zonisamide improves axial symptoms in dementia with Lewy bodies with parkinsonism: Post hoc analysis of clinical trials() |
title_fullStr | Zonisamide improves axial symptoms in dementia with Lewy bodies with parkinsonism: Post hoc analysis of clinical trials() |
title_full_unstemmed | Zonisamide improves axial symptoms in dementia with Lewy bodies with parkinsonism: Post hoc analysis of clinical trials() |
title_short | Zonisamide improves axial symptoms in dementia with Lewy bodies with parkinsonism: Post hoc analysis of clinical trials() |
title_sort | zonisamide improves axial symptoms in dementia with lewy bodies with parkinsonism: post hoc analysis of clinical trials() |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8703232/ https://www.ncbi.nlm.nih.gov/pubmed/34988303 http://dx.doi.org/10.1016/j.ensci.2021.100384 |
work_keys_str_mv | AT tsuboiyoshio zonisamideimprovesaxialsymptomsindementiawithlewybodieswithparkinsonismposthocanalysisofclinicaltrials AT kochikenji zonisamideimprovesaxialsymptomsindementiawithlewybodieswithparkinsonismposthocanalysisofclinicaltrials AT maruyamahidenori zonisamideimprovesaxialsymptomsindementiawithlewybodieswithparkinsonismposthocanalysisofclinicaltrials AT matsumotoyuji zonisamideimprovesaxialsymptomsindementiawithlewybodieswithparkinsonismposthocanalysisofclinicaltrials |